Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 December 2021 | Story Michelle Nothling | Photo Supplied
Lentsu Nchabeleng
Dr Ntheno Nchabeleng was appointed as the Deputy Director in the Gender and Anti-Discrimination Office within the Unit for Institutional Change and Social Justice.

A total of 10 006 rape cases were reported between April and June 2021. This is according to the latest SA crime statistics for the first quarter of 2021/2022. From a sample of 5 439 of these rape cases, 3 766 of incidents took place in the victim’s home or that of the rapist. A shadow pandemic of gender-based violence against our women and children is raging in South Africa.

It is within this global and local context that the Gender and Anti-Discrimination Office (GEADO) at the university is making inroads into supporting survivors of gender-based violence (GBV) and changing gender stereotypes.

GEADO in focus

GEADO is situated within the Unit for Institutional Change and Social Justice on the Bloemfontein Campus. It is mandated to deal with incidents of unfair discrimination and GBV as it relates to the UFS community, and to conduct advocacy and training in these areas. Deputy Director of GEADO, Dr Ntheno Nchabeleng, explains that “through high-impact practices and interventions, the Office works to systematically reduce case attrition to ensure that all reports and cases follow procedurally just processes”.

GEADO has been established at all the UFS campuses with well-trained and fully equipped Senior Gender Officers leading each. Geraldine Langau—supported by research assistant Delisile Mngadi—is managing the office at the Bloemfontein Campus, Chelepe Mocwana the Qwaqwa Campus, and Sivuyisiwe Magayana oversees the South Campus office.

Addressing gender-based violence

Prevention and response to GBV are at the core of GEADO’s work. With our country wracked by sexual violence and femicide, “it has become a nightmare to be a woman in South Africa”, Dr Nchabeleng says.

Its preventative efforts focus on the underlying causes of GBV to transform patriarchal notions, misogynistic norms, power imbalances, and toxic gender stereotypes. Fostering collaboration with various strategic partners to strengthen its impact, GEADO recently started working with Amnesty International Sub-Saharan Africa and Amnesty International Latin America to spread awareness on various forms of violence experienced by vulnerable populations. GEADO has also partnered with other local stakeholders in an effort to eradicate GBV through programming that includes awareness campaigns, online mobilisation, training, and webinars.

Becoming part of the solution

“Become change agents,” Dr Nchabeleng urges. One way to start shifting attitudes and mindsets is to change the way we speak. Examples would be to refrain from sexist and discriminatory language and phrases that undermine and degrade our women. Gendered name-calling generally depicts women and girls as inferior and less than fully human. Another area of concern is the way young people — especially young men — engage in disparaging conversations about women on social media platforms. This behaviour needs to cease. As a society, we also need to stop victim blaming, stop normalising rape culture, and stop entertaining sexual violence jokes,” Dr Nchabeleng says.

These changes start with each of us.

Incidents of GBV and discrimination can be reported to GEADO at:
Bloemfontein Campus: +27 51 401 3982
South Campus: +27 51 401 7544
Qwaqwa Campus: +27 58 718 5431

Sexual Assault Response Team (SART):
www.ufs.ac.za/sart 
Toll-free number +27 80 020 4682

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept